04Ene 2015

J Bone Miner Res. 2015 Jan;30(1):39-45. doi: 10.1002/jbmr.2315.

Together, these findings suggest that the use of denosumab and teriparatide in combination improves HR-pQCT measures of bone quality more than either drug alone and may be of significant clinical benefit in the treatment of postmenopausal osteoporosis.

Autor: Tsai JN, Uihlein AV, Burnett-Bowie SA, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ
04Dic 2014

JAMA. 2014 Dec 3;312(21):2285-6. doi: 10.1001/jama.2014.14038.

Although the optimal rate of bisphosphonate use in men on androgen deprivation therapy (ADT) is unknown, it is reasonable that most men with prior osteoporosis or fracture should be taking a bisphosphonate or other effective bone medication.

Autor: Gulamhusein H, Yun L, Cheung AM, Sutradhar R, Paszat L, Warde P, Alibhai SM.
04Dic 2014
bone logo

Bone 2014; 73:1-7. doi: 10.1016/j.bone.2014.12.003.

Over time, two periods of increased PHPT incidence occurred, one beginning in 1974 (121.7 per 100,000 person-years) and a second peak (86.2 per 100,000 person-years) starting in 1998. The median age of PHPT subjects has increased significantly from 55 years in 1985–1997 to 60 years of age in 1998–2010 and more patients (36%) had a parathyroidectomy in 1998–2010. A second sharp rise in PHPT incidence occurred in our community in 1998, simultaneously with the introduction of national osteoporosis screening guidelines.

Autor: 1. Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ 3rd, Wermers RA.
04Dic 2014

Journal of Bone and Mineral Research, Volume 29, Issue 12, pages 2594–2600. doi: 10.1002/jbmr.2291.

In conclusion, the estimated femoral strength from FE analysis of DXA scans is an independent predictor and performs at least as well as FN BMD in predicting incident hip fracture in postmenopausal women.

Autor: Yang L,, Palermo L, Black DM, Eastell R..
04Dic 2014

Journal of Bone and Mineral Research, Vol. 29, No. 12, December 2014, pp 2537–2544. doi: 10.1002/jbmr.2309.

The studies found that diffuse matrix damage regions in living cortical bone undergo a direct microstructural and mechanically effective repair. The direct repair of these submicron-size cracks in living bone occurs without activating the bone remodeling that are needed to remove larger, typical linear microcrack from bone. The mechanisms responsible for the direct repair of small crack damage in bone are currently under investigation, but given their position in the bone and extensive infiltration throughout the bone matrix, it seems likely that osteocytes play a central role in this direct repair process.

Autor: Seref-Ferlengez Z, Basta-Pljakic J, Kennedy OD, Philemon CJ, Schaffler MB.
04Dic 2014

J Bone Miner Res. 2014 Dec;29(12):2529-33. doi: 10.1002/jbmr.2387.

Accordingly, this Perspective provides evidence that the “undetermined significance” portion of the MGUS acronym may be best replaced in favor of the term “monoclonal gammopathy of skeletal significance” (MGSS) in order to more accurately reflect the enhanced skeletal risks inherent in this condition.

Autor: Drake MT.
04Dic 2014

J Bone Miner Res. 2014 Dec;29(12):2545-51. doi: 10.1002/jbmr.2283

Percentage change from baseline in TH and FN BMD at months 12 and 24 was greater (p < 0.05) in ZOL-treated patients compared with placebo in most subgroups. Treatment-by-subgroup interactions (p <  0.05) indicated that a greater effect on BMD was observed for TH BMD at month 12 in females, in patients in the lower tertile body mass index at baseline (≤22.6 kg/m2), and in patients with baseline FN BMD T-score of ≤ –2.5; for FN BMD in patients who received ZOL for >6 weeks post-surgery; and for TH and FN BMD in patients with a history of one or more prior fractures. All interactions were limited to the first 12 months after treatment with none observed for the 24-month comparisons.

Autor: M.JS,OrwigDL,LylesKW,N.L,BoonenS,AdachiJD,RecknorC,Colón-E.CS,M.P,Bucci-RC,SuG,JohnsonR,PieperCF
04Nov 2014

Calcif Tissue Int. 2014 Dec;95(6):477-94. doi: 10.1007/s00223-014-9923-y

We have conducted a systematic review of all the various aspects of Gaucher disease, focusing on different skeletal manifestations, pathophysiology of bone alterations, clinical symptoms, and current diagnostic and therapeutic approaches.

Autor: 1. Marcucci G, Zimran A, Bembi B, Kanis J, Reginster JY, Rizzoli R, Cooper C, Brandi ML.
05Oct 2014

J Bone Miner Res. 2014 Nov;29(11):2357-68. doi: 10.1002/jbmr.2267.

As in humans, FD lesions in mice developed only in the postnatal life; a defined spatial and temporal pattern characterized the onset and progression of lesions across the skeleton. In individual bones, lesions developed through a sequence of three distinct histopathological stages: a primary modeling phase defined by endosteal/medullary excess bone formation and normal resorption; a secondary phase, with excess, inappropriate remodeling; and a tertiary fibrous dysplastic phase, which reproduced a full-blown replica of the human bone pathology in mice of age ≥1 year. Gsα mutations are sufficient to cause FD, and are per se compatible with germline transmission and normal embryonic development in mice. Our novel murine lines constitute the first model of FD.

Autor: Saggio,Remoli,Spica,Cersosimo,Sacchetti,Robey,Holmbeck,Cumano,Boyde,Bianco,Riminucci
05Oct 2014

J Bone Miner Res. 2014 Nov;29(11):2307-22. doi: 10.1002/jbmr.2373.

Review studies of bone regeneration in genetically modified mouse models, during aging, following environmental exposure, and in the setting of disease that provide insights regarding the role of multipotent cells and their regulation during fracture repair. Complementary animal models and ongoing scientific discoveries define an increasing number of molecular and cellular targets to reduce the morbidity and complications associated with fracture repair. Last, some new and exciting areas of stem cell research such as the contribution of mitochondria function, limb regeneration signaling, and microRNA (miRNA) posttranscriptional regulation are all likely to further contribute to our understanding of fracture repair as an active branch of regenerative medicine.

Autor: Hadjiargyrou M, J O’Keefe RJ.